Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Atea Pharmaceuticals, Inc. (AVIR) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Atea Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1593899.
Total stock buying since 2020: $13,184,266.
Total stock sales since 2020: $2,025,372.
Total stock option exercises since 2020: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 25,000 | $81,490 | 0 | $0 | 517,100 | $0 |
| 2024 | 0 | $0 | 563,073 | $1,810,696 | 571,736 | $0 |
| 2022 | 0 | $0 | 41,666 | $214,676 | 0 | $0 |
| 2021 | 12,000 | $102,792 | 0 | $0 | 0 | $0 |
| 2020 | 541,666 | $12,999,984 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 0 | $0 | 0 | $0 | 177,600 | $0 |
| 2025-01 | 25,000 | $81,490 | 0 | $0 | 339,500 | $0 |
| 2024-12 | 0 | $0 | 359,606 | $1,023,438 | 0 | $0 |
| 2024-09 | 0 | $0 | 57,969 | $234,172 | 0 | $0 |
| 2024-06 | 0 | $0 | 18,550 | $65,164 | 198,900 | $0 |
| 2024-02 | 0 | $0 | 126,948 | $487,922 | 0 | $0 |
| 2024-01 | 0 | $0 | 0 | $0 | 372,836 | $0 |
| 2022-11 | 0 | $0 | 41,666 | $214,676 | 0 | $0 |
| 2021-12 | 12,000 | $102,792 | 0 | $0 | 0 | $0 |
| 2020-11 | 541,666 | $12,999,984 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-20 | Adams Jerome M. | Option Ex | 29,600 | .00 | 0 |
| 2025-06-20 | Lucidi Bruno | Option Ex | 29,600 | .00 | 0 |
| 2025-06-20 | Murphy Polly A. | Option Ex | 29,600 | .00 | 0 |
| 2025-06-20 | Polsky Bruce | Option Ex | 29,600 | .00 | 0 |
| 2025-06-20 | Duncan Barbara Gayle | Option Ex | 29,600 | .00 | 0 |
| 2025-06-20 | Berger Franklin M | Option Ex | 29,600 | .00 | 0 |
| 2025-01-31 | Hammond Janet Mj (Chief Development Officer) | Option Ex | 46,800 | .00 | 0 |
| 2025-01-31 | Vavricka John (Chief Commercial Officer) | Option Ex | 33,333 | .00 | 0 |
| 2025-01-31 | Horga Maria Arantxa (Chief Medical Officer) | Option Ex | 41,533 | .00 | 0 |
| 2025-01-31 | Corcoran Andrea (See Remarks) | Option Ex | 44,367 | .00 | 0 |
| 2025-01-31 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Option Ex | 173,467 | .00 | 0 |
| 2025-01-16 | Berger Franklin M | Buy | 10,000 | 3.36 | 33,610 |
| 2025-01-15 | Berger Franklin M | Buy | 15,000 | 3.19 | 47,880 |
| 2024-12-10 | Berger Franklin M | Sale | 359,606 | 2.85 | 1,023,438 |
| 2024-09-19 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Sale | 1,841 | 4.00 | 7,367 |
| 2024-09-18 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Sale | 22,187 | 4.03 | 89,480 |
| 2024-09-17 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Sale | 33,941 | 4.05 | 137,325 |
| 2024-06-20 | Polsky Bruce | Sale | 17,544 | 3.48 | 61,140 |
| 2024-06-16 | Adams Jerome M. | Option Ex | 33,150 | .00 | 0 |
| 2024-06-16 | Lucidi Bruno | Option Ex | 33,150 | .00 | 0 |
| 2024-06-16 | Murphy Polly A. | Option Ex | 33,150 | .00 | 0 |
| 2024-06-16 | Polsky Bruce | Option Ex | 33,150 | .00 | 0 |
| 2024-06-16 | Duncan Barbara Gayle | Option Ex | 33,150 | .00 | 0 |
| 2024-06-16 | Berger Franklin M | Option Ex | 33,150 | .00 | 0 |
| 2024-06-05 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Sale | 1,006 | 4.00 | 4,024 |
| 2024-02-01 | Hammond Janet Mj (Chief Development Officer) | Sale | 14,029 | 3.84 | 53,913 |
| 2024-02-01 | Vavricka John (Chief Commercial Officer) | Sale | 11,819 | 3.84 | 45,420 |
| 2024-02-01 | Horga Maria Arantxa (Chief Medical Officer) | Sale | 15,870 | 3.84 | 60,956 |
| 2024-02-01 | Foster Wayne (EVP, Chief Accounting Officer) | Sale | 12,477 | 3.84 | 47,899 |
| 2024-02-01 | Corcoran Andrea (See Remarks) | Sale | 15,843 | 3.85 | 60,916 |
| 2024-02-01 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Sale | 56,910 | 3.85 | 218,818 |
| 2024-01-31 | Hammond Janet Mj (Chief Development Officer) | Option Ex | 46,800 | .00 | 0 |
| 2024-01-31 | Vavricka John (Chief Commercial Officer) | Option Ex | 33,334 | .00 | 0 |
| 2024-01-31 | Horga Maria Arantxa (Chief Medical Officer) | Option Ex | 41,534 | .00 | 0 |
| 2024-01-31 | Foster Wayne (EVP, Chief Accounting Officer) | Option Ex | 33,334 | .00 | 0 |
| 2024-01-31 | Corcoran Andrea (See Remarks) | Option Ex | 44,367 | .00 | 0 |
| 2024-01-31 | Sommadossi Jean-pierre (President, CEO, and Chairman) | Option Ex | 173,467 | .00 | 0 |
| 2022-11-14 | Berger Franklin M (Director) | Sale | 16,166 | 5.16 | 83,351 |
| 2022-11-11 | Berger Franklin M (Director) | Sale | 25,500 | 5.15 | 131,325 |
| 2021-12-20 | Murphy Polly A. (Director) | Buy | 12,000 | 8.57 | 102,792 |
| 2020-11-03 | Rock Springs Capital Llc (10% Owner) | Buy | 250,000 | 24.00 | 6,000,000 |
| 2020-11-03 | Hack Andrew A. F. (Director) | Buy | 250,000 | 24.00 | 6,000,000 |
| 2020-11-03 | Berger Franklin M (Director) | Buy | 41,666 | 24.00 | 999,984 |
Insider trading activities including stock purchases, stock sales, and option exercises of AVIR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Atea Pharmaceuticals, Inc. (symbol AVIR, CIK number 1593899) see the Securities and Exchange Commission (SEC) website.